

## Bibliografia

- Adham, N., Kao, H. T., Schechter, L. E. et al., 1993. Cloning of another human serotonin receptor (5-HT<sub>1F</sub>): a fifth 5-HT<sub>1</sub> receptor subtype coupled to the inhibition of adenylate cyclase. *Proc. Natl. Acad. Sci.* 90, 408-412.
- Al-Hurula, V., Myllyla, V. V., Arvela, P. et al., 1979. Systemic availability of ergotamine tartarate after three successive doses and during continuous medication. *Eur. J. Clin. Pharmacol.* 16, 355-360.
- Andermann, F., 1987. Migraine-epilepsy relationships. *Epilepsy Res* 1, 213-26.
- Bax, W. A., Renzenbrink, G. J., Van Heuven-Nolsen, D. et al., 1993. 5-HT receptors mediating contractions of the isolated human coronary artery. *Eur. J. Pharmacol.* 239, 203-210.
- Baxter, G., Kenneth, G., Blaney, F. et al., 1995. 5-HT<sub>2</sub> receptor subtypes: a family reunited? *TiPS.* 16, 105-110.
- Beatie, D. T., Connor, H. E., 1995. The pre- and postjunctional activity of CP-122,288, a conformationally restricted analogue of sumatriptan. *Eur. J. Pharmacol.* 276, 271-276.
- Boers, P. M., Donaldson, C., Zagami, A.S. et al., 2004. Naratriptan has a selective inhibitory effect on trigeminovascular neurones at central 5-HT<sub>1A</sub> and 5-HT<sub>1B/1D</sub> receptors in the cat: implications for migraine therapy. *Cephalalgia* 24, 99-109.
- Bogouslavsky, J., Regli, F., 1987. Ischemic stroke in adults younger than 30 years of age. Cause and prognosis. *Arch Neurol* 44, 479-82.
- Boska, M. D., Welch, K. M., Schultz, L. et al., 2000. Effects of the anti-migraine drug sumatriptan on muscle energy metabolism: relationship to side-effects. *Cephalalgia* 20, 39-44.
- Bouchelet, I, Case, B., Olivier, A. et al., 2000. No contractile effect for 5-HT<sub>1F</sub> receptor agonists in human and bovine cerebral arteries: similarity with human coronary artery. *Br. J. Pharmacol.* 129, 501-508.
- Bouchelet, I., Cohen, Z., Case, B. et al., 1996. Differential expression of sumatriptan-sensitive 5-hydroxytryptamine receptors in human trigeminal ganglia and cerebral blood vessels. *Molecular Pharmacology* 60, 219-223.

Breslau, N., Davis, G. C., 1993. Migraine, physical health and psychiatric disorder: a prospective epidemiologic study in young adults. *J Psychiatr Res* 27, 211-21.

Breslau, N., Davis, G. C., Schultz, L. R. et al., 1994. Joint 1994 Wolff Award Presentation. Migraine and major depression: a longitudinal study. *Headache* 34, 387-93.

Brewerton, T. D., Murphy, D. L., Mueller, E. A. et al., 1988. Induction of migraine like headaches by the serotonin agonist m-chlorophenylpiperazine. *Clin. Pharmacol. Ther.* 43, 605-609.

Burnstein, R., Woolf, C. J., 2000. Central sensitization and headache, in: Olesen, J., Tfelt-Hansen, P., Welch, K. M. A., (Eds), *The Headaches*, Second Edition, Lippincott Williams and Wilkins, Philadelphia, USA, pp125-131.

Buzzi, M. G., Bonamini, M., Moskowitz, M. A., 1995. Neurogenic model of migraine. *Cephalalgia* 15, 277-280.

Buzzi, M. G., Moskowitz, M. A., 1990. The antimigraine drug sumatriptan (GR 43175), selectively blocks neurogenic plasma extravasation from blood vessels in duramater. *Br. J. Pharmacol*, 99, 202-206.

Buzzi, M. G., Sakas, D. E., Moskowitz, M. A., 1989. Indomethacin and acetylsalicylic acid block neurogenic plasma protein extravasation in rat dura mater. *Eur. J. Pharmacol.* 165, 251-258.

Castro, M. E., Pascual, J., Romon, T. et al., 1997. Differential distribution of [<sup>3</sup>H]sumatriptan binding sites (5-HT<sub>1B</sub>, 5-HT<sub>1D</sub> and 5-HT<sub>1F</sub> receptors) in human brains: focus on brainstem and spinal cord. *Neuropharmacology* 36, 535-542.

Cavazos, J. E., Caress, J. B., Chilukuri, V. R. et al., 1994. sumatriptan-induced stroke in saggital sinus thrombosis. *Lancet* 343, 1105-1106.

Celentano, D. D., Stewart, W. F., Lipton, R. B. et al., 1992. Medication use and disability among migraineurs: a national probability sample survey. *Headache* 32, 223-8.

Classification committee of the International Headache Society, 1988. Classification and diagnostic criteria for headache disorders, cranial neuralgias and facial pain. *Cephalalgia* 8(Suppl 7), 1-96.

- Cohen, M. L., Schenck, K., 1999. 5-Hydroxytryptamine<sub>1F</sub> receptors do not participate in vasoconstriction to LY344864, a selective serotonin<sub>1F</sub> receptor agonist in rabbit saphenous vein. *J. Pharmacol. Exp. Ther.* 290, 935-939.
- Connor, H. E., Beattie, D. T., 1999. 5-Hydroxytryptamine receptor subtypes: relation to migraine, in: Edvinsson, L. (Ed.), *Migraine and Headache Pathophysiology*. Martin Dunitz Ltd, London, UK, pp 43-52.
- Connor, H. E., Feniuk, W., Beattie, D. T. et al., 1997. Naratriptan : biological profile in animal models relevant to migraine. *Cephalalgia* 17, 145-152.
- Connor, H. E., Feniuk, W., Humphrey, P. P. A., 1989a. 5-Hydroxytryptamine contracts human coronary arteries predominantly via 5-HT<sub>2</sub> receptor activation. *Eur. J. Pharmacol.* 161, 91-94.
- Connor, H. E., Feniuk, W., Humphrey, P. P. A., 1989b. Characterization of 5-HT receptors mediating contraction of canine and primate basilar artery by use of GR 43175, a selective 5-HT<sub>1</sub> – like receptor agonist. *Br. J. Pharmacol.* 96, 379-387.
- Corso, D. M., Pucino, F., DeLeo, J. M. et al., 1992. Development of a questionnaire for detecting potential adverse drug reactions. *Ann Pharmacother* 26, 890-6.
- Cortijo, J., Marti-Cabrera, M., Bernabeu, E. et al., 1997. Characterization of 5-HT receptors on human pulmonary artery and vein: functional and binding studies. *Br. J. Pharmacol.* 122, 1455-1463.
- Dahlof, C. G. H., Dodick, D., Dowson, A. J., 2002. How does almotriptan compare with other triptans? A review of data from placebo-controlled clinical trials. *Headache* 42, 99-113.
- Dahlof, C., Linde, M., 2001. One-year prevalence of migraine in Sweden: a population-based study in adults. *Cephalalgia* 21, 664-71.
- Dahlof, C. G., Mathew, N., 1998. Cardiovascular safety of 5HT<sub>1B/1D</sub> agonists--is there a cause for concern? *Cephalalgia* 18, 539-45.
- Deckert, V., Angus, J. A., 1992. Evidence that 5-HT<sub>2</sub> receptors predominantly mediate the contraction of the rat basilar artery to 5-hydroxytryptamine. *Eur. J. Pharmacol.* 221, 17-25.
- Diener, H. C., 1997. Positron emission tomography studies in headache. *Headache* 37, 622-625.

Diener, H. C., 2003. RPR100893, a substance-P antagonist, is not effective in the treatment of migraine attacks. *Cephalalgia* 23, 183-5.

Dodick, D. W., 2004a. Introduction: cardiovascular safety and triptans in the acute treatment of migraine. *Headache* 44 (Suppl 1), S1-4.

Dodick, D. W., 2004b. Triptans and chest symptoms: the role of pulmonary vasoconstriction. *Cephalalgia* 24, 298-304.

Dodick, D. W., Martin, V. T., Smith, T. et al., 2004. Cardiovascular tolerability and safety of triptans: a review of clinical data. *Headache* 44 (Suppl 1), S20-30.

Edvinsson, L., 1999. On migraine pathophysiology, in: Edvinsson, L. (Ed.), *Migraine and Headache Pathophysiology*. Martin Dunitz Ltd, London, UK, pp 3-15.

Edvinsson, L., Brodin, E., Jansen, I. et al., 1988. Neurokinin A in cerebral vessels: characterization, localization, coexistence and effects *in vitro*. *Regul. Peptides* 20, 181-197.

Edvinsson, L., Cantera, L., Jansen-Olesen I. et al., 1997. Calcitonin gene-related peptide<sub>1</sub> receptor mRNA in human trigeminal ganglia and cerebral arteries. *Neurosci. Lett.* 229, 209-211.

Edvinsson, L., Degueurce, A., Duverger, D. et al., 1983a. Central serotonergic nerves project to the pial vessels of the brain. *Nature* 306, 55-57.

Edvinsson, L., Ekman, R., Jansen, I. et al., 1987a. Calcitonin gene-related peptide and cerebral blood vessels: distribution and vasomotor effects. *J. Cereb. Blood Flow Metab.* 7, 720-728.

Edvinsson, L., Ekman, R., Jansen, I. et al., 1987b. Peptide-containing nerve fibres in human cerebral arteries: immunocytochemistry, radioimmunoassay and *in vitro* pharmacology. *Ann. Neurol.* 21, 432-37.

Edvinsson, L., MacKenzie, E. T., McCulloch, J., 1993. *Cerebral Blood Flow and Metabolism*. Raven Press, New York, USA.

Edvinsson, L., Mulder, H., Goadsby, P. J. et al., 1998. Calcitonin gene-related peptide and nitric oxide in the trigeminal ganglion. Cerebral vasodilatation from trigeminal nerve stimulation involves mainly calcitonin gene-related peptide. *J. Auton. Nerv. Syst.* 70, 15-22.

- Edvinsson, L., Rosendahl-Helgesen, S., Uddman, R., 1983b. Substance P. Localization, concentration and release in cerebral arteries, choroid plexus and dura mater. *Cell. Tissue Res.* 234, 1-7.
- Edvinsson, L., Uddman, E., Wackenfors, A. et al., 2005. Triptan-induced contractile (5-HT<sub>1B</sub> receptor) responses in human cerebral and coronary arteries: relationship to clinical effect. *Clinical Science* 109, 335-342.
- Edwards, I. R., Biriell, C., 1994. Harmonisation in pharmacovigilance. *Drug Saf.* 10, 93-102.
- Eglen, R. M., Jasper, J. R., Chang, D. J. et al., 1997. The 5-HT<sub>7</sub> receptor: orphan found. *Trends Pharmacol. Sci.* 18, 104-107.
- Ferrari, M. D., Goadsby, P. J., Roon, K. I. et al., 2002. Triptans (serotonin, 5-HT<sub>1B/1D</sub> agonists) in migraine: detailed results and methods of a meta-analysis of 53 trials. *Cephalalgia* 22, 633-58.
- Ferrari, M. D., Odink, J., Tapparelli, C. et al., 1989. Serotonin metabolism in migraine. *Neurology* 39, 1239-1242.
- Ferrari, M. D., Roon, K. I., Lipton, R. B. et al., 2001. Oral triptans (serotonin, 5-HT<sub>1B/1D</sub> agonists) in acute migraine treatment: a meta-analysis of 53 trials. *Lancet* 358, 1668-1675.
- Featherstone, H. J., 1985. Migraine and muscle contraction headaches: a continuum. *Headache* 25, 194-8.
- Fleishaker, J. C., Pearson, L. K., Knuth, D. W. et al., 1999. Pharmacokinetics and tolerability of a novel 5-HT<sub>1D</sub> agonist, PNU-142633F. *Int J Clin Pharmacol Ther* 37, 487-92.
- Fontes Ribeiro, C. A., Macedo, T. R. A., Porfírio, M. H., 1991. Pharmacological characterization of the postsynaptic serotonergic receptor in the human uterine artery. *Pharmacology.* 43, 264-272.
- Forster, C., Whalley, E. T., 1982. Analysis of the 5-hydroxytryptamine induced contraction of the human basilar arterial strip compared with the rat aortic strip in vitro. *Naunyn Schmiedeberg's Arch. Pharmacol.* 319, 12-17.
- Frants, R. R., Ophoff, R. A., Terwindt, G. M. et al., 1998. The future of headache genetics, in: Olesen J., Bouser M.-G., (Eds.), *Genetics of Headache Disorders*. Lippincott-Raven, New York, USA.
- Frenken, M., 1989. Evidence for two populations of 5-hydroxytryptamine receptors in dog basilar artery. *J. Pharmacol. Exp. Ther.* 250, 379-387.

Friberg, L., Olesen, J., Iversen H. K. et al., 1991. Migraine pain associated with middle cerebral artery dilatation: reversal by sumatriptan. *Lancet*. 338, 13-17.

Garcia-del-Pozo, J., Carvajal, A., Grajal, C. et al., 2003. Antimigraine drug consumption in Spain (1990-2000). *Acta Neurol Scand* 107, 158-60.

Gaynor, R., Herschman, H. R., Irie, R. et al., 1981. S100 protein: a marker for human malignant melanomas? *Lancet* 1, 869-71.

Geerts, I.S., De Meyer, G.R.Y. et al., 2000. Collar-induced elevation of mRNA and functional activity of 5-HT<sub>1B</sub> receptor in the rabbit carotid artery. *Br. J. Pharmacol.* 131, 1723-1731.

Giffin, N. J., Kowacs, F., Libri, V. et al., 2003. Effect of the adenosine A1 receptor agonist GR79236 on trigeminal nociception with blink reflex recordings in healthy human subjects. *Cephalalgia* 23, 287-92.

Goadsby, P. J., 2004. Prejunctional and presynaptic trigeminovascular targets: what preclinical evidence is there? *Headache Currents* 1, 1-6.

Goadsby, P. J., Edvinsson, L., 1993. The trigeminovascular system and migraine: studies characterizing cerebrovascular and neuropeptide changes seen in human and cats. *Ann. Neurol.* 33, 48-56.

Goadsby, P. J., Edvinsson, L., 1994. Peripheral and central trigeminovascular activation in cat is blockade by the serotonin 5-HT<sub>1D</sub> receptor agonist 311C90. *Headache* 34, 394-399.

Goadsby, P. J., Edvinsson, L., Ekman, R., 1990. Vasoactive peptide release in the extracerebral circulation of humans during migraine headache. *Ann. Neurol.* 28, 183-187.

Goadsby, P. J., Hoskin, K. L., Storer, R. J. et al., 2002. Adenosine A1 receptor agonists inhibit trigeminovascular nociceptive transmission. *Brain* 125, 1392-401.

Goadsby, P. J., Lipton, R. B., Ferrari, M. D., 2002. Migraine-current understanding and treatment. *N Engl J Med* 346, 257-70.

Goadsby, P. J., Zagami, A. S., 1991. Stimulation of the superior sagittal sinus increases metabolic activity and blood flow in certain regions of the brainstem and upper cervical spinal cord of the cat. *Brain* 114, 1001-1004.

- Goadsby, P. J., Zagami, A. S., Lambert, G. A., 1991. Neural processing of craniovascular pain: a synthesis of the central structures involved in migraine. *Headache* 31, 365-371.
- Goldstein, D. J., Roon, K. I., Offen, W. W. et al., 2001. Selective serotonin 1F (5-HT<sub>1F</sub>) receptor agonist LY334370 for acute migraine: a randomised controlled trial. *Lancet* 358, 1230-4.
- Goldstein, D. J., Wang, O., Saper, J. R. et al., 1997. Ineffectiveness of neurokinin-1 antagonist in acute migraine: a crossover study. *Cephalalgia* 17, 785-790.
- Gomez-Mancilla, B., Cutler, N. R., Leibowitz, M. T. et al., 2001. Safety and efficacy of PNU-142633, a selective 5-HT<sub>1D</sub> agonist, in patients with acute migraine. *Cephalalgia* 21, 727-32.
- Guimarães, S., Brandão, F., Paiva, M.Q., 1978. A study of the adrenoceptor-mediated feedback mechanisms by using adrenaline as a false transmitter. *Naunyn-Schmiedeberg's Arch. Pharmacol.* 305, 185-188.
- Guimarães, S., Moura, D., 2001. Vascular adrenoceptors: an update. *Pharmacol Rev* 53, 319-356.
- Gul, H. and Yildiz, O., 2002. Amplification of sumatriptan-induced contractions with phenylephrine, histamine and KCl in the isolated human mesenteric artery: in-vitro evidence for sumatriptan-induced mesenteric ischaemia. *Naunyn Schmiedebergs Arch Pharmacol* 366, 254-61.
- Hadjikhani, N., Sanchez Del Rio, M., Wu, O. et al., 2001. Mechanisms of migraine aura revealed by functional MRI in human visual cortex. *Proc Natl Acad Sci U S A* 98, 4687-92.
- Hall, G. C., Brown, M. M., Mo, J. et al., 2004. Triptans in migraine: the risks of stroke, cardiovascular disease, and death in practice. *Neurology* 62, 563-8.
- Hamel, E., Fan, E., Linville, D. et al., 1993. Expression of mRNA for the serotonin 5-hydroxytryptamine 1D $\beta$  receptor subtype in human and bovine cerebral arteries. *Molecular Pharmacology* 44, 242-246.
- Hargreaves, R. J., Williamson, D. J., Shephard, S. I., 1999. Neurogenic inflammation: relation to novel antimigraine drugs, in: Edvinsson, L. (Ed.), *Migraine and Headache Pathophysiology*. Martin Dunitz Ltd, London, UK, pp 93-101.

Hartig, P. R., Hoyer, D., Humphrey, P. P. et al., 1996. Alignment of receptor nomenclature with the human genome: classification of 5-HT<sub>1B</sub> and 5-HT<sub>1D</sub> receptor subtypes. *Trends Pharmacol Sci* 17, 103-5.

Head, R. J., Panek, K. R., Reid, J. et al., 1986. O-methylation of isoproterenol by the endothelium of the rabbit thoracic aorta. *Blood vessels* 23, 279-287.

Henry, P., Michel, P., Brochet, B. et al., 1992. A nationwide survey of migraine in France: prevalence and clinical features in adults. *GRIM. Cephalalgia* 12, 229-37; discussion 186.

Honey, A. C., Bland-Ward, P. A., Connor, H. E. et al., 2002. Study of an adenosine A1 receptor agonist on trigeminally evoked dural blood vessel dilation in the anaesthetized rat. *Cephalalgia* 22, 260-4.

Houghton, L. A., Foster, J. M., Whorwell, P. J. et al., 1994. Is chest pain after sumatriptan oesophageal in origin? *Lancet* 344, 985-6.

Hovdal, H., Syverson, G. B., Roenthaler, J., 1982. Ergotamine in plasma and CFS after i.m. and rectal administration to humans. *Cephalalgia* 2, 145-150.

Hoyer, D., Clarke, D. E., Fozard, J. R. et al., 1994. VII. International Union of Pharmacology classification of receptors for 5-hydroxytryptamine (serotonin). *Pharmacological Reviews* 46, 157-203.

Hoyer, D., Martin, G. R., 1997. 5-HT receptor classification and nomenclature: towards a harmonization with the human genome. *Neuropharmacology* 36, 419-428.

Humphrey, P. P. A., 1991. 5-Hydroxytryptamine and the pathophysiology of migraine. *J. Neurol.* 238, (Suppl 1) S38-S44.

Humphrey, P. P. A., Feniuk, W., 1991. Mode of action of the anti-migraine drug sumatriptan. *Trends. Pharmacol. Sci.* 12, 444-446.

Humphrey, P. P. A., Feniuk, W., Perren, M. J. et al., 1989. The pharmacology of the novel 5-HT<sub>1</sub>-like receptor agonist, GR43175. *Cephalalgia* 9 (Suppl 9), 23-33.

Humphrey, P. P. A., Goadsby, P. J., 1994. The mode of action of sumatriptan is vascular? A debate. *Cephalalgia* 14, 401-410.

Inan, L. E., Tulunay, F. C., Guvener, A. et al., 1994. Characteristics of headache in migraine without aura and episodic tension-type headache in



the Turkish population according to the IHS classification. *Cephalalgia* 14, 171-3.

Iovino, M., Feifel, U., Yong, C. L. et al., 2004. Safety, tolerability and pharmacokinetics of BIBN 4096 BS, the first selective small molecule calcitonin gene-related peptide receptor antagonist, following single intravenous administration in healthy volunteers. *Cephalalgia* 24, 645-56.

Jackowski, A., Crockard, A., Burnstock, G., 1989. 5-Hydroxytryptamine demonstrated immunohistochemically in rat cerebrovascular nerves largely represents 5-hydroxytryptamine uptake into sympathetic nerve fibres. *Neuroscience* 29, 453-462.

Jansen, I., Edvinsson, L., Mortensen, A. et al., 1992. Sumatriptan is a potent vasoconstrictor of human dural arteries via a 5-HT<sub>1</sub>-like receptor. *Cephalalgia* 12, 202-205.

Johnson, E. S., Ratcliffe, D. M., Wilkinson, M., 1985. Naproxen sodium in the treatment of migraine. *Cephalalgia* 5, 5-10.

Johnson, K. W., Schaus, J. M., Durkin, M. M. et al., 1997. 5-HT<sub>1F</sub> receptor agonist inhibit neurogenic dural inflammation in guinea pigs. *NeuroReport* 8, 2237-2240.

Karlsson, C., Bodelsson, G., Bodelsson, M., et al., 1997. 5-Hydroxytryptamine contracts human uterine artery smooth muscle predominantly via 5-HT<sub>2</sub> receptors. *Human Reproduction*. 12, 361-367.

Karlsson, C., Bodelsson, G., Bodelsson, M. et al., 1999. Characterization of 5-hydroxytryptamine receptors mediating circular smooth muscle contraction in the human umbilical artery. *Gynecol. Obstet. Invest.* 47, 102-107.

Kaube, H., Hoskin, K. L., Goadsby, P. J., 1993b. Intravenous acetylsalicylic acid inhibits trigeminal neurons in the dorsal horn of the upper cervical spinal cord in the cat. *Headache* 33, 541-544.

Kaube, H., Keay, K., Hoskin, K. L. et al., 1993a. Expression of c-fos-like immunoreactivity in the trigeminal nucleus caudalis and high cervical cord following stimulation of the sagittal sinus in the cat. *Brain Res.* 629, 95-100.

Kaumann, A.J., Frenken, M., Posival, H. et al., 1994. Coronary heart disease/myocardial infarction: Variable participation of 5-HT<sub>1</sub>-like receptors and 5-HT<sub>2</sub> receptors in serotonin-induced contraction of human isolated coronary arteries. 5-HT<sub>1</sub>-like receptors resemble cloned 5-HT<sub>1Dβ</sub> receptors. *Circulation* 90, 1141-1153.

Kempski, O., von Rosen, S., Weigt, H. et al., 1991. Glial ion transport and volume control. *Ann. N. Y. Acad. Sci.* 633, 306-317.

Knudsen, J. F., Friedman, B., Chen, M. et al., 1998. Ischemic colitis and sumatriptan use. *Arch Intern Med* 158, 1946-8.

Knudsen, J. F., Friedman, B., Chen, M. et al., 1998. Ischemic colitis and sumatriptan use. *Arch Intern Med* 158, 1946-8.

Kryst, S., Scherl, E., 1994. A population-based survey of the social and personal impact of headache. *Headache* 34, 344-50.

Lacey, L. F., Hussey, E. K., Fowler, P. A., 1995. Single dose pharmacokinetics of sumatriptan in healthy volunteers. *Eur. J. Clin. Pharmacol.* 47, 543-548.

Lacombe, P., Sercombe, R., Correze, J. L. et al., 1992. Spreading depression induces prolonged reduction of cortical blood flow reactivity in the rat. *Exp. Neurol.* 117, 278-286.

Laemmli, U. K., 1970. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. *Nature* 227, 680-685.

Lafitte, C., Even, C., Henry-Lebras, F. et al., 1996. Migraine and angina pectoris by coronary artery spasm. *Headache* 36, 332-4.

Lambert, G. A., Lowy, A. J., Boers, P. M. et al., 1992. The spinal cord processing of input from the superior sagittal sinus: pathway and modulation by ergot alkaloids. *Brain Res.* 597, 321-330.

Landy, S., Rice, K., Lobo, B., 2004. Central sensitisation and cutaneous allodynia in migraine: implications for treatment. *CNS Drugs* 18, 337-342.

Lassen, L. H., Ashina, M., Christiansen, I. et al., 1997. Nitric oxide synthase inhibition in migraine. *Lancet.* 349, 401-402.

Launer, L. J., Terwindt, G. M., Ferrari, M. D., 1999. The prevalence and characteristics of migraine in a population-based cohort: the GEM study. *Neurology* 53, 537-42.

Lauritzen, M., Olesen, J., 1984. Regional cerebral blood flow during migraine attacks by Xenon-133 inhalation and emission tomography. *Brain* 107, 447-461.

Lauritzen, M., Skyhoj Olsen, T., Lassen, N. A., et al., 1983. The changes of regional cerebral blood flow during the course of classical migraine attacks. *Ann. Neurol.* 13, 633-641.

Leão, A. A. P., 1944. Spreading depression of activity in the cerebral cortex. *J. Neurophysiol.* 7, 359-390.

Lee, W. S., Moskowitz, M. A., 1993. Conformationally restricted sumatriptan analogues, CP-122,288 and CP-122,638 exhibit enhanced potency against neurogenic inflammation in dura mater. *Brain Res.* 626, 303-305.

Leira, R., Lainez, J. M., Pascual, J. et al., 1998. [Spanish study of quality of life in migraine (I). Profile of the patient with migraine attending neurology clinics]. *Neurologia* 13, 287-91.

Lew, M. J., MacPherson, G. A., 1996. Isolated tissue techniques, in: Garland, C. J. and Angus, J. A. (Eds), *Pharmacology of vascular smooth muscle*, Oxford University Press Inc., New York, USA, pp 25-41.

Leysen, J. E., Gommeren, W., Heylen, L. et al., 1996. Alniditan, a new 5-hydroxytryptamine<sub>1D</sub> agonist and migraine-abortive agent: ligand-binding properties of human 5-hydroxytryptamine<sub>1D</sub> alpha, human 5-hydroxytryptamine<sub>1D</sub> beta, and calf 5-hydroxytryptamine<sub>1D</sub> receptors investigated with [<sup>3</sup>H]5-hydroxytryptamine and [<sup>3</sup>H]alniditan. *Mol Pharmacol* 50, 1567-80.

Lincoln, J., 1995. Innervation of cerebral arteries by nerves containing 5-hydroxytryptamine and noradrenaline. *Pharmac. Ther.* 68, 473-501.

Lipton, R. B., Diamond, S., Reed, M. et al., 2001. Migraine diagnosis and treatment: results from the American Migraine Study II. *Headache* 41, 638-45.

Lipton, R. B., Silberstein, S. D., 1994. Why study the comorbidity of migraine? *Neurology* 44, S4-5.

Liu, J. J., Ardolf, J. C., 2000. Sumatriptan-associated mesenteric ischemia. *Ann Intern Med* 132, 597.

Longmore, J., Hargreaves, R. J., Boulanger, C. M. et al., 1997b. Comparison of the vasoconstrictor properties of the 5-HT<sub>1D</sub>-receptor agonists rizatriptan (MK-462) and sumatriptan in human isolated coronary artery: outcome of two independent studies using different experimental protocols. *Functional Neurology* 12, 3-9.

Longmore, J., Razzaque Z., Shaw, D. et al., 1998. Comparison of the vasoconstrictor effects of rizatriptan and sumatriptan in human isolated cranial arteries: immunohistological demonstration of the involvement of 5-HT<sub>1B</sub>-receptors. *Br. J. Clin. Pharmacol.* 46, 577-582.

Longmore, J., Shaw, D., Smith, D. et al., 1997a. Differential distribution of 5-HT<sub>1D</sub> and 5HT<sub>1B</sub> immunoreactivity within the human trigeminocerebrovascular system: implications for the discovery of new antimigraine drugs. *Cephalalgia* 17, 833-842.

Maassen VanDenBrink, A., Reekers, M., Bax, W. A. et al., 1998. Coronary side-effect potential of current and prospective antimigraine drugs. *Circulation* 98, 25-30.

MacKinnon, A. C., Spedding, M. and Brown, C. M., 1994. Alpha 2-adrenoceptors: more subtypes but fewer functional differences. *Trends Pharmacol Sci* 15, 119-23.

Markowitz, S., Saito, K., Moskowitz, M. A., 1987. Neurogenically mediated leakage of plasma protein occurs from blood vessels in dura mater but not brain. *J. Neurosci.* 7, 4129-4136.

Markowitz, S., Saito, K., Moskowitz, M. A., 1988. Neurogenically mediated plasma extravasation in dura mater: effects of ergot alkaloids. A possible mechanism of action in vascular headache. *Cephalalgia* 8, 83-91.

Martin, G. R., 1996. Inhibition of the trigemino-vascular system with 5-HT<sub>1D</sub> agonist drugs: selectively targeting additional sites of action. *Eur. Neurol.* 36 (Suppl 2), 13-18.

Martin, G. R., 1997. Pre-clinical pharmacology of zolmitriptan (Zomig; formerly 311C90), a centrally and peripherally acting 5-HT<sub>1B/1D</sub> agonist for migraine. *Cephalalgia* 17 (Suppl 18), 4-14.

Martin, G. R., Rhodes, P., Mills, A., 1999. Autoradiographic mapping of receptors and recognition sites for established and putative antimigraine drugs, in: Edvinsson, L. (Ed.), *Migraine and Headache Pathophysiology*. Martin Dunitz Ltd, London, UK, pp 63-79.

Martin, G. R., Robertson, A. D., MacLennan, S. J. et al., 1997. Receptor specificity and trigemino-vascular inhibitory actions of a novel 5-HT<sub>1B/1D</sub> receptor partial agonist, 311C90 (zolmitriptan). *Br. J. Pharmacol.* 121, 157-164.

May, A., Gijsman, H. J., Wallnofer, A. et al., 1996. Endothelin antagonist bosentan blocks neurogenic inflammation, but is not effective in aborting migraine attacks. *Pain* 67, 375-378.

May, A., Shephard, S. L., Knorr et al., 1998. Retinal plasma extravasation in animals but not in humans: implications for the pathophysiology of migraine. *Brain* 121, 1231-1237.

- McComb, R. D., Jones, T. R., Pizzo, S. V. et al., 1982. Specificity and sensitivity of immunohistochemical detection of factor VIII/von Willebrand factor antigen in formalin-fixed paraffin-embedded tissue. *J Histochem Cytochem* 30, 371-7.
- McDowell, I., Newell, C., 1996. The theoretical and technical foundations of health measurement, in: McDowell, I., Newell, C. (Eds), *Measuring Health: a guide to rating scales and questionnaires*, 2<sup>nd</sup> Edition, Oxford university Press, New York, USA, pp 10-46.
- Mies, G., Pashen, W., 1984. Regional changes of blood flow, glucose and ATP content determined from brain sections during a single passage of spreading depression in the rat brain cortex. *Exp. Neurol.* 84, 249-258.
- Miller, D., Waters, D. D., Warnica, W. et al., 1981. Is variant angina the coronary manifestation of a generalized vasospastic disorder? *N Engl J Med* 304, 763-6.
- Miyamoto, A., Obi, T., Nishio, A., 1996. The vasomotor effects of 5-hydroxytryptamine on equine basilar arteries in vitro. *Vet. Res. Commun.* 20, 61-70.
- Miyamoto, A., Sakota, T., Nishio, A., 1994. Characterization of 5-hydroxytryptamine receptors on the isolated pig basilar artery by functional and radioligand binding studies. *Jpn. J. Pharmacol.* 65, 265-273.
- Morecroft, I., Heeley, R. P., Prentice, H. M. et al., 1999. 5-hydroxytryptamine receptors mediating contraction in human small muscular pulmonary arteries: importance of the 5-HT<sub>1B</sub> receptor. *Br. J. Pharmacol.* 128, 730-734.
- Moskowitz, M. A., 1984. The neurobiology of vascular head pain. *Ann. Neurol.* 16, 157-168.
- Moskowitz, M. A., 1991. The visceral organ brain: Implications for the pathophysiology of vascular head pain. *Neurology* 41, 182-186.
- Moskowitz, M. A., 1992. Neurogenic versus vascular mechanisms of sumatriptan and ergot alkaloids in migraine. *Trends Pharmacol. Sci.* 13, 307-311.
- Moskowitz, M. A., Nozaki, N., Kraig, R. P., 1993. Neocortical spreading depression provokes the expression of *c-fos* protein-like immunoreactivity within trigeminal nucleus caudalis via trigeminovascular mechanism. *J. Neurosci.* 13, 1167-1177.

Napier, C., Stewart, M., Melrose, H. et al., 1999. Characterisation of the 5-HT receptor binding profile of eletriptan and kinetics of [<sup>3</sup>H]eletriptan binding at human 5-HT<sub>1B</sub> and 5-HT<sub>1D</sub> receptors. *Eur J Pharmacol* 368, 259-68.

Nappi, G., Sandrini, G., Sances, G., 2003. Tolerability of the triptans: clinical implications. *Drug Saf* 26, 93-107.

Newman-Tancredi, A., Conte, C., Chaput, C. et al., 1997. Agonist activity of antimigraine drugs at recombinant human 5-HT<sub>1A</sub> receptors: potential implications for prophylactic and acute therapy. *Naunyn Schmiedeberg Arch Pharmacol* 355, 682-8.

Nilsson, T., Longmore, J., Shaw, D. et al., 1999a. Characterization of 5-HT receptors in human coronary arteries by molecular and pharmacological techniques. *Eur. J. Pharmacol.* 372, 49-56.

Nilsson, T., Longmore, J., Shaw, D. et al., 1999b. Contractile 5-HT<sub>1B</sub> receptors in human cerebral arteries: pharmacological characterization and localization with immunocytochemistry. *Br. J. Pharmacol.* 128, 1133-1140.

Nissila, M., Parkkola, R., Sonninen, P. et al., 1996. Intracerebral arteries and gadolinium enhancement in migraine without aura. *Cephalalgia* 16, 363.

O'Brien, B., Goeree, R., Streiner, D., 1994. Prevalence of migraine headache in Canada: a population-based survey. *Int J Epidemiol* 23, 1020-6.

Olesen, J., 1993. Migraine: Hemodynamics, in: Olesen, J., Tfelt-Hansen, P., Welch, K. M. A., (Eds), *The Headaches*, Raven Press, Ltd., New York, USA, pp 209-222.

Olesen, J., Diener, H. C., Husstedt, I. W. et al., 2004. Calcitonin gene-related peptide receptor antagonist BIBN 4096 BS for the acute treatment of migraine. *N Engl J Med* 350, 1104-10.

Olesen, J., Friberg, L., Olsen, T. S. et al., 1990. Timing and topography of cerebral blood flow, aura and headache during migraine attacks. *Ann. Neurol.* 28, 791-798.

Olesen, J., Larsen, B., Lauritzen, M., 1981. Focal hyperemia followed by spreading oligemia and impaired activation of rCBF in classic migraine. *Ann. Neurol.* 9, 344-352.

Olesen, J., Thomsen, L. L., Lassen, L. H. et al., 1995. The nitric oxide hypothesis of migraine and other vascular headaches. *Cephalalgia* 15, 94-100.

- Ophoff, R. A., Terwindt, G. M., Vergouwe M. N. et al., 1996. Familial hemiplegic migraine and episode ataxia type-2 are caused by mutations in the  $Ca^{2+}$  channel gene CACNL1A4. *Cell* 87, 543-552.
- Ottervanger, J. P., Paalman, H. J., Boxma, G. L. et al., 1993a. Transmural myocardial infarction with sumatriptan. *Lancet* 341, 861-2.
- Ottervanger, J. P., Valkenburg, H. A., Grobbee, D. E. et al., 1997a. Characteristics and determinants of sumatriptan-associated chest pain. *Arch Neurol* 54, 1387-92.
- Ottervanger, J. P., van Witsen, T. B., Valkenburg, H. A. et al., 1993b. Postmarketing study of cardiovascular adverse reactions associated with sumatriptan. *Bmj* 307, 1185.
- Ottervanger, J. P., Wilson, J. H., Stricker, B.H., 1997b. Drug-induced chest pain and myocardial infarction. Reports to a national centre and review of the literature. *Eur. J. Clin. Pharmacol.* 53, 105-110.
- Papademetriou, V., 2004. Cardiovascular risk assessment and triptans. *Headache* 44 (Suppl 1), S31-9.
- Parker, E.M., Grisel, D.A., Iben, L.G., 1993. A single amino acid differences accounts for the pharmacological distinctions between the rat and human 5-hydroxytryptamine receptors. *J. Neurochem.* 60, 380-3.
- Parsons, A. A., Whalley, E. T., 1989. Evidence for the presence of 5-HT<sub>1</sub>-like receptors in rabbit isolated basilar arteries. *Eur. J. Pharmacol.* 174, 189-196.
- Parsons, A. A., Whalley, E. T., Feniuk, W. et al., 1989. 5-HT<sub>1</sub>-like receptors mediate 5-hydroxytryptamine-induced contraction of human isolated basilar artery. *Br. J. Pharmacol.* 96, 434-449.
- Pascual, J., Lainez, J. M., Leira, R. et al., 2003. [Almotriptan in the treatment of migraine attacks in clinical practice: results of the TEA 2000 observational study]. *Neurologia* 18, 7-17.
- Pascual, J., Leira, R., Lainez, J. M. et al., 1999. [Spanish study of quality of life in migraine (II). Profile of medication consumption and subjective efficacy]. *Neurologia* 14, 204-9.
- Pauwels, P.J., Wurch, T., Palmier, C. et al., 1998. Pharmacological analysis of G-protein activation mediated by guinea-pig recombinant 5-HT<sub>1B</sub> receptors in C6-glia cells: similarities with the human 5-HT<sub>1B</sub> receptor. *Br. J. Pharmacol.* 123, 51-62.

Peatfield, R. C., 1999. Migraine: which triptan? *Hospital Medicine* 60, 277-280.

Pereira Monteiro, J. M., 1995. Cefaleias: estudo epidemiológico e clínico de uma população urbana. Dissertação de Doutoramento, Instituto de Ciências Biomédicas Abel Salazar, Universidade do Porto, Porto, Portugal.

Pereira Monteiro, J. M., Matos, E., Calheiros, J. M., 1994. Headaches in medical school students. *Neuropharmacology* 13, 103-107.

Perren, M. J., Feniuk, W., Humphrey, P. P. A., 1991. Vascular 5-HT<sub>1</sub>-like receptors that mediate contraction of dog isolated saphenous vein and carotid arterial vasoconstriction in anaesthetized dogs are not of the 5-HT<sub>1A</sub> or 5-HT<sub>1D</sub> subtype. *Br. J. Pharmacol.* 102, 191-197.

Perry, C., Markham, A., 1998. Sumatriptan – An updated review of its use in migraine. *Drugs* 55, 889-922.

Pestana, M. H., Gageiro, J. N., 2003. Análise de dados para ciências sociais – a complementaridade do SPSS. 3ª Edição, Edições Sílabo, Lda., Lisboa, Portugal.

Pilgrim, A. J., 1994. The clinical profile of sumatriptan: efficacy in migraine. *Eur. Neurol.* 34 (Suppl 2), 26-34.

Piper, R. D., Lambert, G. A., Duckworth, J. W., 1991. Cortical blood flow changes during spreading depression in cats. *Am J. Physiol.* 261, H96-102.

Pradalier, A., Rancurel, G., Dordain, G., et al., 1985. Acute migraine attack therapy: Comparison of naproxen sodium and an ergotamine tartarate compound. *Cephalalgia* 5, 107-113.

Price, G. W., Burton, M. J., Collin, L. J., et al., 1997. SB-216641 and BRL-15572 – compounds to pharmacologically discriminate h5-HT<sub>1B</sub> and h5-HT<sub>1D</sub> receptors. *Naunyn-Schmiedeberg's Arch. Pharmacol.* 356, 312-320.

Quarto, M., Diaz, G., Floris, A., et al., 1992. Calcitonin gene-related peptide in the human trigeminal sensory system at developmental and adult life stages: immunohistochemistry, neuronal morphometry and coexistence with substance P. *J. Chem. Neuroanat.* 5, 143-157.

Ramadan, N. M., Buchanan, T. M., Pearlman, S. H., 2004. Peripheral and central trigeminal targets for migraine therapy: early clinical trials results. *Headache Currents* 1, 7-12.



Ramadan, N. M., Halvorson, H., Vande-Linde, A. et al., 1989. Low brain magnesium in migraine. *Headache* 29, 416-419.

Rasmussen, B. K., 1995. Epidemiology of headache. *Cephalalgia* 15, 45-68.

Rasmussen, B. K., Jensen, R., Olesen, J., 1991b. Questionnaire versus clinical interview in the diagnosis of headache. *Headache* 31, 290-5.

Rasmussen, B. K., Jensen, R., Schroll, M. et al., 1991a. Epidemiology of headache in a general population-a prevalence study. *J Clin Epidemiol* 44, 1147-57.

Rasmussen, B. K., Olesen, J., 1992. Migraine with aura and migraine without aura: an epidemiological study. *Cephalalgia* 12, 221-8; discussion 186.

Razzaque, Z., Heald, M. A., Pickard, J. D., et al., 1999. Vasoconstriction in human isolated middle meningeal arteries: determining the contribution of 5-HT<sub>1B</sub> – and 5-HT<sub>1F</sub> – receptor activation. *Br. J. Clin. Pharmacol.* 47, 75-82.

Razzaque, Z., Pickard, J. D., Ma, Q.-P., et al., 2002. 5-HT<sub>1B</sub>-receptors and vascular reactivity in human isolated blood vessels: assessment of the potential craniovascular selectivity of sumatriptan. *Br J. Clin. Pharmacol.* 53, 266-274.

Rebeck, G. W., Maynard, K. I., Hyman, B. T. et al., 1994. Selective 5-HT<sub>1D $\alpha$</sub>  serotonin receptor gene expression in trigeminal ganglia: implications for antimigraine drug development: *Proc. Natl. Acad. Sci. USA* 91, 3666-3669.

Rees, D. D., Palmer, R. M., Schulz, R. et al., 1990. Characterization of three inhibitors of endothelial nitric oxide synthase in vitro and in vivo. *Br. J. Pharmacol.* 101, 746-752.

Reinhard, J. F., Liebmann, J. E., Schosberg, A. J. et al., 1979. Serotonin neurons project to small blood vessels in the brain. *Science* 206, 85-87.

Rosamond, W., 2004. Are migraine and coronary heart disease associated? An epidemiologic review. *Headache* 44 (Suppl 1), S5-12.

Roon, K., Diener, H. C., Ellis, P. et al., 1997. CP-122-288 blocks neurogenic inflammation, but is not effective in aborting migraine attacks: results of two controlled clinical trials. *Cephalalgia* 17, 245.

Roon, K. I., Maassen Van Den Brink, A., Ferrari, M. D. et al., 1999. Bovine isolated middle cerebral artery contractions to antimigraine drugs. *Naunyn Schmiedebergs Arch Pharmacol* 360, 591-6.

Russel, M. B., Olesen, J., 1995. Increased familial risk and evidence of a genetic factor in migraine. *BMJ* 311, 541-544.

Sang, C. N., Ramadan, N. M., Wallihan, R. G. et al., 2004. LY293558, a novel AMPA/GluR5 antagonist, is efficacious and well-tolerated in acute migraine. *Cephalalgia* 24, 596-602.

Schmechel, D., Marangos, P. J. and Brightman, M., 1978. Neurone-specific enolase is a molecular marker for peripheral and central neuroendocrine cells. *Nature* 276, 834-6.

Schoeffter, P., Ullmer, C., Bobirnac, I. et al., 1996. Functional, endogenously expressed 5-hydroxytryptamine 5-HT<sub>7</sub> receptors in human vascular smooth muscle cells. *Br J Pharmacol* 117, 993-4.

Schumck, K., Ullmer, C., Kalkman, H. O. et al., 1996. Activation of meningeal 5-HT<sub>2B</sub> receptors: an early step in the generation of migraine headache? *Eur. J. Neurosci.* 8, 956-967.

Selkirk, J. V., Scott, C., Ho, M. et al., 1998. SB-224289 – a novel selective (human) 5-HT<sub>1B</sub> receptor antagonist with negative intrinsic activity. *Br. J. Pharmacol.* 125, 202-208.

Sheftell, F. D., Feleppa, M., Tepper, S. J. et al., 2004. Assessment of adverse events associated with triptans-methods of assessment influence the results. *Headache* 44, 978-82.

Sheftell, F. D., Fox, A. W., 2000. Acute migraine treatment outcome measures: a clinician's view. *Cephalalgia* 20 (Suppl 2), 14-24.

Shinohara, M., Dollinger, B., Brown, G. et al., 1979. Cerebral glucose utilisation: local changes during and after recovery from spreading cortical depression. *Science* 203, 188-190.

Sicuteri, F. Testi, A., Anselmi, B., 1961. Biochemical investigation in headache: increase in the hydroxyindoleacetic acid excretion during migraine attacks. *Int Arch Allerg* 19, 55-58.

Silberstein, S. D., 2004. Migraine pathophysiology and its clinical implications. *Cephalalgia* 24 (Suppl 2), 2-7.

Silberstein, S. D., Lipton, R. B., Goadsby, P. J., 1998a. Historical introduction, in: Silberstein, S. D., Lipton, R. B., Goadsby, P. J. (Eds.), *Headache in Clinical Practice*, Isis Medical Media, Oxford, UK, pp 1-8.

Silberstein, S. D., Lipton, R. B., Goadsby, P. J., 1998b. Epidemiology and impact of headache disorders, in: Silberstein, S. D., Lipton, R. B., Goadsby, P. J. (Eds.), *Headache in Clinical Practice*, Isis Medical Media, Oxford, UK, pp 19-30.

Silberstein, S. D., Lipton, R. B., Goadsby, P. J., 1998c. The pathophysiology of primary headache, in: Silberstein, S. D., Lipton, R. B., Goadsby, P. J. (Eds.), *Headache in Clinical Practice*, Isis Medical Media, Oxford, UK, pp 41-58.

Silberstein, S. D., Lipton, R. B., Goadsby, P. J., 1998d. Migraine: Diagnosis and treatment, in: Silberstein, S. D., Lipton, R. B., Goadsby, P. J., (Eds.), *Headache in Clinical Practice*, Isis Medical Media, Oxford, UK, pp 61-90.

Silberstein, S. D., Saper, J., Freitag, F. G., 2001. Migraine: diagnosis and treatment, in: Silberstein, S. D., Lipton, R. B., Dalessio, D. J., (Eds), *Wolff's Headache and Other Head Pain*, 7<sup>th</sup> Edition, Oxford University Press, New York, pp 121-237.

Spierings, E. L., Gomez-Mancilla, B., Grosz, D. E. et al., 2001. Oral almotriptan vs. oral sumatriptan in the abortive treatment of migraine: a double-blind, randomized, parallel-group, optimum-dose comparison. *Arch Neurol* 58, 944-50.

Stewart, W. F., Lipton, R. B., Celentano, D. D. et al., 1992. Prevalence of migraine headache in the United States. Relation to age, income, race, and other sociodemographic factors. *Jama* 267, 64-9.

Strassman, A., Mason, P., Moskowitz, M. A. et al., 1986. Response of brainstem trigeminal neurones to electrical stimulation of the dura. *Brain Res.* 379, 242-250.

Strom, B. L., 1994. Study designs available for pharmacoepidemiology studies, in: Strom, B. L., (Ed), *Pharmacoepidemiology*, 2<sup>nd</sup> Edition, John Wiley & Sons, pp 15-27.

Subcomissão de Classificação das Cefaleias da Sociedade Internacional de Cefaleias, 2005. Classificação Internacional das Cefaleias. *Sinapse* 5 (Supl 1), 1-128.

Telft-Hansen, P., De Vries, P., Saxena, P. R., 2000. Triptans in migraine: a comparative review of pharmacology, pharmacokinetics and efficacy. *Drugs* 60, 1259-1287.

Tepper, S. J., 2001. safety and rational use of the triptans. *Headache* 85, 959-970.

Terron, J. A., 2002. Is the 5-HT<sub>7</sub> receptor involved in the pathogenesis and prophylactic treatment of migraine? *Eur J Pharmacol* 439, 1-11.

Terron, J. A., Bouchelet, I., Hamel, E., 2001. 5-HT<sub>7</sub> receptor mRNA expression in human trigeminal ganglia. *Neurosci Lett* 302, 9-12.

Thomsen, L. L., Iversen, H. K., Brinck T. A. et al., 1993. Arterial supersensitivity to nitric oxide (nitroglycerin) in migraine sufferers. *Cephalalgia* 13, 395-399.

Toda, N., Okamura, T., Shimizu, I. et al., 1985. Postmortem functional changes in coronary and cerebral arteries from humans and monkeys. *Cardiovasc Res* 19, 707-13.

Ullmer, C., Schmuck, K., Kalkman, H. O. et al., 1995. Expression of serotonin receptor mRNAs in blood vessels. *FEBS Lett* 370, 215-21.

van den Broek, R. W., Bhalla, P., VanDenBrink, A. M. et al., 2002. Characterization of sumatriptan-induced contractions in human isolated blood vessels using selective 5-HT<sub>1B</sub> and 5-HT<sub>1D</sub> receptor antagonists and in situ hybridization. *Cephalalgia* 22, 83-93.

Van den Broek, R. W. M., Maassen VanDenBrink, A., De Vries, R. et al., 2000. Pharmacological analysis of contractile effects of eletriptan and sumatriptan on isolated blood vessels. *Eur. J. Pharmacol.* 407, 165-173.

Velentgas, P., Cole, J. A., Mo, J. et al., 2004. Severe vascular events in migraine patients. *Headache* 44, 642-51.

Verheggen, R., Hundeshagen, A. G., Brown, A. M., et al., 1998. 5-HT<sub>1B</sub> receptor-mediated contractions in human temporal artery: evidence from selective antagonists and 5-HT receptor mRNA expression. *Br. J. Pharmacol.* 124, 1345-1354.

Vijayan, N., Peacock, J. H., 2000. Spinal cord infarction during use of zolmitriptan: a case report. *Headache* 40, 57-60.

Visser, W. H., de Vriend, R. H., Jaspers, M. W. et al., 1996a. Sumatriptan in clinical practice: a 2-year review of 453 migraine patients. *Neurology* 47, 46-51.

Visser, W. H., Jaspers, N. M., de Vriend, R. H. et al., 1996b. Chest symptoms after sumatriptan: a two-year clinical practice review in 735 consecutive migraine patients. *Cephalalgia* 16, 554-9.

- Waller, P., Arlett, P., 2002. Part I – Basis of pharmacovigilance. Responding to signals, in: Mann, R., Andrews, E., (Eds), Pharmacovigilance, 2<sup>nd</sup> Edition, John Wiley & Sons.
- Weiller, C., May, A., Limmroth, V. et al., 1995. Brain stem activation in spontaneous human migraine attacks. *Nature Med.*1, 658-660.
- Welch, K. M. A., 1993. Drug therapy of migraine. *N Engl J Med* 329, 1476-1483.
- Welch, K. M., 1994. Relationship of stroke and migraine. *Neurology* 44, S33-6.
- Welch, K. M., Mathew, N. T., Stone, P. et al., 2000. Tolerability of sumatriptan: clinical trials and post-marketing experience. *Cephalalgia* 20, 687-95.
- Willems, E. W., Valdivia, L. F., Villalón, C. M. et al., 2003. Possible role of  $\alpha$ -adrenoceptor subtypes in acute migraine therapy. *Cephalalgia* 23, 245-257.
- Willett, F., Curzen, N., Adams, J. et al., 1992. Coronary vasospasm induced by subcutaneous sumatriptan. *Bmj* 304, 1415.
- Williamson, D. J., Hargreaves, R. J., Hill, R. G. et al., 1997a. Intravital microscope studies on the effects of neurokinin agonists and calcitonin gene-related peptide on dural vessel diameter in the anaesthetised rat. *Cephalalgia* 17, 518-524.
- Williamson, D. J., Hargreaves, R. J., Hill, R. G. et al., 1997b. Sumatriptan inhibits neurogenic vasodilation of dural blood vessels in the anaesthetized rat-intravital microscope studies. *Cephalalgia* 17, 525-31.
- Witting, M. D., 1996. Renal papillary necrosis following emergency department treatment of migraine. *J Emerg Med* 14, 373-6.
- Wolff, H. G., 1963. Headache and Other Head Pain. Oxford University Press, New York, USA.
- Woods, R. P., Iacobini, M., Mazziota, J. C., 1994. Brief report: bilateral spreading cerebral hypoperfusion during spontaneous migraine headache. *N. Engl. J. Med.* 331, 1689-1692.
- Yu, J. G., Lee, T. J. F., 1989. 5-Hydroxytryptamine-containing fibers in cerebral arteries of the cat, rat and guinea pig. *Blood Vessels* 26, 33-43.

Zifa, E., Fillion, G., 1992. 5-Hydroxytryptamine receptors. *Pharmacol Rev* 44, 401-458.